Metabolic Research Market

C-Peptide

The native 31-residue connecting peptide released from proinsulin in equimolar amounts with insulin, used clinically as the standard laboratory marker of beta-cell function; a PEGylated replacement form for diabetic neuropathy failed in phase 2b in 2014.

ProinsulinBeta-Cell FunctionDiabetes BiomarkerType 1 DiabetesNot FDA Approved

Also appears in: Hormone

Public product evidence No certificate records are bound to a tracked C-Peptide product page A record counts here only when a vendor publishes a certificate against one of its own tracked C-Peptide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Metabolic signaling research

Primary research area: Metabolic. Also surfaces under Hormone for browsing and discovery.

Body systems
Hormones · Brain

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 2 trials · 1000 PubMed results

Promising

C-Peptide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

C-Peptide has 2 name-matched clinical trials (highest phase: Phase 2) and 1000 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet. Note: 3 retracted publications in the literature.

⚠ 3 retracted publications
Human data
Phase 2
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
  1. 2026-11-17 Preclinical → Promising Band Preclinical → Promising; +2 trials
  2. 2026-11-17 Preclinical First graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is C-Peptide?

C-peptide, the connecting peptide of proinsulin, is the 31-amino-acid segment that joins the B chain to the A chain of insulin in the single-chain precursor. In human preproinsulin (UniProt P01308) it occupies residues 57 to 87, with the sequence Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln (EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ), flanked by the dibasic Arg-Arg and Lys-Arg sites that the prohormone convertases cut; the free peptide has a molecular weight of about 3,020 Da. It is acidic, lacks cysteine and aromatic residues, and is far less conserved across species than insulin, which for decades suggested it had no function beyond helping the insulin chains fold and pair. The single-chain precursor was established by Donald Steiner’s laboratory in 1967 (Steiner et al., Science, 1967;157(3789):697–700).

Every molecule of insulin leaves the beta cell with one molecule of C-peptide. Unlike insulin, C-peptide undergoes little first-pass extraction by the liver and is cleared mainly by the kidney, so its concentration in blood or urine is the standard clinical readout of endogenous insulin secretion, and that diagnostic role is the only use that has reached routine medicine. A second line of work, started in the 1990s, argued that C-peptide is itself a hormone whose absence contributes to the microvascular complications of type 1 diabetes; a PEGylated replacement form reached phase 2b before failing in 2014, and no C-peptide drug product has ever been approved anywhere. Synthetic human C-peptide is sold as a research reagent and appears in the research-peptide market.

How it works

  • Saturable, G-protein-dependent binding to human cells. Fluorescence correlation spectroscopy showed labeled C-peptide binding specifically to renal tubular cells and other human cell types, saturating at low nanomolar concentrations; the C-terminal pentapeptide displaced the ligand, scrambled and all-D peptides did not compete, insulin and proinsulin did not cross-react, and pertussis toxin abolished binding, pointing to a G protein-coupled receptor (Rigler et al., Proceedings of the National Academy of Sciences, 1999;96(23):13318–13323). Knockdown of the orphan receptor GPR146 blocked C-peptide-induced c-Fos expression in KATOIII cells (Yosten et al., Journal of Endocrinology, 2013;218(2):B1–B8), but CHO-K1 cells expressing human GPR146 showed no response to C-peptide at up to 33 µM (Lindfors et al., Bioorganic and Medicinal Chemistry Letters, 2020;30(13):127208).
  • Stimulation of Na+,K+-ATPase. In single rat proximal tubules, C-peptide raised Na+,K+-ATPase activity between 10 nM and 1 µM, with neuropeptide Y shifting the response into the picomolar range; pertussis toxin and FK506 abolished the effect (Ohtomo et al., Diabetologia, 1996;39(2):199–205).
  • Endothelial nitric oxide release. In bovine aortic endothelial cells, physiological concentrations of C-peptide more than doubled nitric oxide production through calcium influx and activation of the calcium-sensitive endothelial nitric oxide synthase, without changing eNOS mRNA levels (Wallerath et al., Nitric Oxide, 2003;9(2):95–102).
  • Chirality-independent effects in rats. Human C-peptide prevented or attenuated vascular and neural dysfunction and the fall in Na+,K+-ATPase activity in diabetic rats, but reverse-sequence and all-D-amino-acid versions were equipotent, which the authors read as nonchiral membrane interactions rather than a stereospecific receptor (Ido et al., Science, 1997;277(5325):563–566). That result conflicts with the stereospecific binding later reported from Karolinska.

Research status

The diagnostic evidence base is large and settled. In the Diabetes Control and Complications Trial, detectable mixed-meal-stimulated C-peptide at entry was associated with lower rates of retinopathy, nephropathy and severe hypoglycemia (Steffes et al., Diabetes Care, 2003;26(3):832–836), and the relationship proved continuous: a 50% higher stimulated C-peptide at entry meant an 8.2% lower hypoglycemia risk and a 25% lower risk of sustained retinopathy in the intensive-treatment group, with no threshold (Lachin et al., Diabetes, 2014;63(2):739–748). Among 944 DCCT/EDIC participants with an average 35 years of diabetes, 12.4% still had a measurable meal response, and a peak C-peptide above 0.03 nmol/L was associated with markedly less severe hypoglycemia (Gubitosi-Klug et al., Journal of Clinical Investigation, 2021;131(3):e143011); ultrasensitive assays found stimulated C-peptide in 54 of 74 (73%) people with long-duration type 1 diabetes (Oram et al., Diabetologia, 2014;57(1):187–191). Clinically, C-peptide separates type 1 from type 2 and monogenic diabetes in insulin-treated patients, with the greatest value 3 to 5 years after diagnosis, and the spot urine C-peptide-to-creatinine ratio has made outpatient measurement practical (Jones and Hattersley, Diabetic Medicine, 2013;30(7):803–817; Besser et al., Diabetes Care, 2011;34(2):286–291). The joint ADA-EASD consensus report on type 1 diabetes in adults incorporates C-peptide testing into its classification algorithm (Holt et al., Diabetes Care, 2021;44(11):2589–2625), and an updated consensus report was published in September 2026 (Holt et al., Diabetes Care, 2026).

C-peptide as a trial endpoint. An American Diabetes Association workshop report concluded that stimulated C-peptide is the most suitable primary outcome for trials aimed at preserving beta-cell function in type 1 diabetes (Palmer et al., Diabetes, 2004;53(1):250–264), and a 2024 review argued that the accumulated data qualify it as a validated surrogate for clinical benefit (Latres et al., Diabetes, 2024;73(6):823–833). At a Critical Path Institute public workshop in June 2025, regulatory participants stated that C-peptide is not considered a validated surrogate endpoint sufficient on its own for traditional approval, but that it meets the threshold of a reasonably likely surrogate endpoint able to support accelerated approval with a postmarketing requirement to confirm clinical benefit.

Replacement therapy: the Swedish trials. The Karolinska group ran small, double-blind, placebo-controlled studies of native human C-peptide in type 1 diabetes. In 21 patients with microalbuminuria studied in a crossover design, 3 months of C-peptide (600 nmol per 24 hours) reduced urinary albumin excretion from 58 to 34 µg/min (P < 0.01) and increased respiratory heart-rate variability by 21% in the 12 with signs of autonomic neuropathy (Johansson et al., Diabetic Medicine, 2000;17(3):181–189). In 49 patients without neuropathy symptoms, 3 months of the same dose improved sural sensory nerve conduction velocity by 2.7 ± 0.85 m/s versus placebo (P < 0.05) (Ekberg et al., Diabetes, 2003;52(2):536–541). The largest native-peptide study, a 6-month dose-finding trial registered by Creative Peptides Sweden as NCT00278980, randomized patients at five centers to 1.5 mg/day or 4.5 mg/day of C-peptide or placebo; among 139 completers with a mean diabetes duration of 30.6 years, conduction velocity improved similarly within both C-peptide groups (P < 0.007), but the 1.0 m/s gain reached significance against placebo only in the 70 least affected patients (P < 0.014) (Ekberg et al., Diabetes Care, 2007;30(1):71–76).

Cebix and CBX129801 (Ersatta). Cebix Incorporated of San Diego, California, developed a PEGylated synthetic human C-peptide, CBX129801, for once-weekly subcutaneous injection. A placebo-controlled multiple-ascending-dose study in 72 patients (NCT01293461, phase 1/2, April 2011 to August 2012) preceded the pivotal trial. A 39-week toxicology study in cynomolgus monkeys found no systemic adverse effects at plasma concentrations several hundred times the physiological 1 to 3 nmol/L, with findings limited to macrophage vacuolization at injection sites and draining lymph nodes (Naas et al., International Journal of Toxicology, 2015;34(4):318–324). The pivotal phase 2b (NCT01681290; EudraCT 2012-001246-17) randomized 250 patients with type 1 diabetes of at least 5 years’ duration, C-peptide deficiency and mild to moderate peripheral neuropathy to weekly CBX129801 0.8 mg (n = 71), 2.4 mg (n = 73) or placebo (n = 106) for 52 weeks, with bilateral sural sensory nerve conduction velocity as the primary endpoint. After 52 weeks, conduction velocity had increased by 1.0 ± 0.24 m/s in the combined C-peptide groups and by 1.2 ± 0.29 m/s on placebo, so the primary endpoint was not met; other electrophysiological measures and the modified Toronto Clinical Neuropathy Score were also unchanged. Vibration perception threshold on the great toe did improve, by 25% from baseline (−4.5 ± 1.0 µm versus −0.1 ± 0.9 µm; P < 0.001) (Wahren et al., Diabetes Care, 2016;39(4):596–602). Primary completion was November 2014; no results were posted, and the registry entry was last updated on January 30, 2015.

After Cebix. No company has taken up C-peptide replacement since. The only interventional study of administered C-peptide registered as active in November 2026 is an academic, early phase 1 basic-science crossover study at the University of Cincinnati (NCT06470295), which infuses C-peptide intravenously during insulin-induced hypoglycemia to test whether it raises glucagon secretion. Reviews by the replacement program’s originators still describe C-peptide as a bioactive peptide with therapeutic potential (Wahren and Larsson, Diabetes Research and Clinical Practice, 2015;107(3):309–319), but the only adequately powered trial was negative on its primary and clinical endpoints and no confirmatory human study has followed.

Common dosage forms

  • No approved presentation. No C-peptide drug product is approved or marketed in any country.
  • Investigational solutions for subcutaneous injection. Native human C-peptide was supplied to Swedish trial sites as a solution for subcutaneous injection, and CBX129801 (Ersatta) was a PEGylated C-peptide solution for subcutaneous injection in the Cebix trials; neither exists outside those completed studies.
  • Laboratory reagents. Synthetic human C-peptide is sold as a lyophilized peptide for research use and as calibrators and controls for clinical immunoassays.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of any FDA-approved or FDA-pending C-peptide drug product and of any active US development program aimed at approval. The only company-sponsored program, Cebix’s PEGylated CBX129801, ended after its phase 2b trial failed in 2014; the single active registered study of administered C-peptide is an academic physiology study, and the molecule’s established clinical role is as a laboratory measurement.
  • A measurement, not a medicine. The clinical value of C-peptide rests on what its concentration reveals about endogenous insulin secretion: classification of diabetes type, prediction of hypoglycemia risk and the primary endpoint of beta-cell preservation trials. None of that evidence speaks to any effect of administering the peptide.
  • The replacement hypothesis failed its one definitive test. Small Swedish trials of native C-peptide reported gains in nerve conduction, albuminuria and autonomic function, but the 250-patient, 52-week phase 2b of long-acting C-peptide showed no benefit over placebo on nerve conduction velocity or clinical neuropathy score. A positive secondary finding on vibration perception in a trial that missed its primary endpoint does not establish efficacy.
  • Mechanism unsettled. Stereospecific binding and the GPR146 proposal are contradicted by equipotent retro and all-D peptides in rats and by the absence of GPR146 signaling in a heterologous expression system, so no validated receptor exists for the peptide.
  • Safety record is short and incomplete. Human exposure is limited to roughly 12 months in a few hundred trial participants, with a 9-month primate study finding no systemic toxicity; long-term effects of supraphysiological C-peptide levels were never characterized.